PCNA as prognostic factor of brcast câncer clinicai stage II
Keywords:
immunohistochemistry, Breast câncer, PCNA, Prognostic factorAbstract
The purpose of this work was to study the proliferating cell nuclear antigen (PCNA) of
women with breast câncer clinicai stage II and correlate it with the patienfs evolution. A
retrospective study of 74 women from the mastology ciinic at the São Francisco University
Hospital in Bragança Paulista was carried out. These women were treated with surgery, and
those who presented axillary lymphonodal involvement received adjuvant therapy with
chemotherapy, radiotherapy and hormonetherapy. The average follow-up was 68.7 months
and the average age was 53.1 years (range: 30-82 years o/d). Regarding the overall survival
and disease-free survivai there was no significant difference from these resuits. We conduded
that the PCNA should not be considered a prognostic factor, in our cases, for patients with
breast câncer clinicai stage II.
Downloads
References
1.AGARWAL S, JAIN R, RUSIA U, GUPTA, RL. Proliferating cell nuclear antigen
immunostaining in breast carcinoma and
its relationship to clinicai and pathological
variables. Indian J Pathol Microbiol 1997;
40: 11-6.
2.AGRESTI A. Categorical data analysis. New York: Editora John Wiley. 1990;
576.
3.ALLRED DG, HARVEY JM, BERARDO M, CLARK
GM. Prognostic and predictive factors in
breast câncer by immunohistochemical
analysis. Mod Pathol 1998; 11: 155-68.
4.BIANCHI S, PAGLIERANI M, ZAMPI G et
ai. Prognostic value of proliferating cell
nuclear antigen in lymph node negative
breast câncer patients. Câncer 1993;
72: 120-5.
5.CLARK GM. Do we really need prognostic
factors for breast câncer? Breast Câncer
ResTreat 1994; 30: 117-26.
6.COLLETT D. Modelling survival data in medicai research. Editora Chapman &
Hall. 1994; 384.
7.CUMMINGS MC, FURNIVAL CM, PARSONS
PG, TOWNSEND E. PCNA immunostaining
in breast câncer. Aust N Z J Surg 1993;
63: 630-6.
8.DENOIX P. New trends in the diagnosis
and treatment of câncer. Rer Inst Nac Cancerol 1970; 22: 674-80.
9.GADELHA MIP, SALTZ E, REZENDE MCR, PI- NHEIRO LR. Câncer: um problema de saúde pública no Brasil. JBM 1992; 63: 38-45.
10.GARCIA RL, COLTRERA MD, GOWN AM. Analysis of proliferative grade using anti
PCNA/cyclin monoclonal antibodies in
fixed, embedded tissues. Am J Pathol
1989; 134: 733-9.
11.GASPARINIS, MELI S, POZZA S, CAZZAVILLAN S, BELIACQUA P. PC-10
antibody to proliferating cell nuclear
antigen (PCNA) is not related to
prognosis in human breast carcinomas. Growth Reg 1992; 2: 145-50.
12.GERSHON-COHEN J, BERGER SM, KLICKSTEIN HS. Roentgenography of
breast câncer moderating concept of "biologic
predeterminism". Câncer 1963;
16: 961-4.
13.HAERSLEV TH, JACOBSEN GK. Proliferating
cell nuclear antigen in breast carcinomas:
an immunohistochemical study with
correlation to histopathological features
and prognostic factors. Virchows Archiv
1994; 424: 39-46.
14.HERCHENHORN D, REZENDE LM, THULER
LC, MAIA RC, MEDINA M, COSTA MDC.
Quimioterapia neo-adjuvante em câncerde mama localmente avançado: análise imunoistoquímica é preditiva da resposta à quimioterapia. Rev Bras
Cancerol 2000; 46: 163-71.
15.INCA - INSTITUTO NACIONAL DE CÂNCER. Ministério da Saúde. Estimativas
da incidência e mortalidade por câncer
no Brasil.[2001 julho 25], Disponível
em: .
16.KEMP C. Valor prognóstico do antígeno
nuclear de proliferação celular (PCNA/
ciclina) em pacientes com câncer de mama (T2 N0,1 MO). São Paulo: 1995.
Tese de Doutorado, Unifesp/EPM.
17.KESARI AL, CHELLAM VG, NAIR PP etal.
Tumor proliferative fraction in infiltrating
ductcarcinoma. Gen Diagn Pathol 1997;
143: 219-24.
18.KESARI AL, CHELLAM VG, NAIR PP et ai
p53 tumor suppressor protein and tissue
proliferative fraction in infiltrating duct carcinoma. J Surg Oncol 1997; 65: 159-63.
19.MATHEWS MB, BERNSTEIN RM, FRANZA
Jr BR, GARRELS JI. Identity of the
proliferating cell nuclear antigen and
cyclin. Nature 1984; 309: 374-6.
20.PUGLISI F, Dl LORETO C, BELTRAMI CA.
Fattori prognostico-predittivi e scelte
terapeutiche nel carcinoma invasivo
delia mammella. Ann Ital Chir 1999; 3:
335-41.
21.SANTINHO MJ, SOUZA AZ, FARIA RM,
SALVATORE CA. Aspectos imunoistológicos
e prognósticos do carcinoma da mama.
Ginecol Obstet Bras 1982; 5: 307-25.
22.SCHMITT FC. Marcadores prognósticos em carcinoma mamário. In: Alves VAF, Bacchi CE, Vassalo J. (eds.). Manual de imunoistoquímica. Sociedade Brasileira de Patologia; 1999;
30-46.
23.SCHÕNBORN I, ZSCHIESCHE W, MINGUILLON C. et al. Prognostic value
of proliferating cell nuclear antigen and
c-erbB-2 compared with conventional
histopathological factors in breast
câncer. J Câncer Res Clin Oncol 1995;
121: 115-22.
24.SHEEN-CHEN SM, ENG HL, CHOU FF, CHEN WJ. The prognostic significance
of Proliferating Cell Nuclear Antigen in
patients with lymph node positive
breast câncer. Arch Surg 1997; 132:
264-7.
25.SILVA HMS, COELHO JrJL. Fatores aplicações clínicas. J Bras Ginec 1987; 97:
371-4.
26.SILVA HMS, COELHO Jr JL, VIANNA LL
et al. Fatores prognósticos: estudo em
90 casos de câncer de mama. J Bras Ginec 1991; 101: 109-13.
27.TAHAN SR, NEUBERG DS, DIEFFENBACH
A, YACOUB L. Prediction of early relapse
and shortened survival in patients with
breast câncer by proliferating cell nuclear
antigen score. Câncer 1993; 71: 3552-9.
28.UICC - UNIÃO INTERNACIONAL CONTRA O CÂNCER. TNM Classification of malignant tumors. 4 ed., Springer
Verlag. 1987.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Olavo Pedroso Cezar lunior, Gustavo Antonio de Souza, Marcelo Alvarenga
This work is licensed under a Creative Commons Attribution 4.0 International License.
